SGVector is helping to address the global shortage in viral vectors

What we aim to do

Establish Viral Vector suspension-based scale manufacturing process/technologies in Singapore.

Set up and operate a modular cGMP facility for the development and production of viral vectors for gene therapies.

Demand

The FDA continues with strong support of Innovation in Development of Gene Therapy Products. The agency anticipates many more approvals in the coming years, as evidenced by the circa 1000 Investigational New Drug applications for ongoing clinical studies in this area. The agency believes this will provide patients and providers with increased therapeutic choices. The growth of innovative research and product development in the field of gene therapy is exciting. These therapies are rapidly becoming a therapeutic reality for an increasing number of patients with a wide range of diseases, including rare genetic disorders and autoimmune diseases.

 

The FDA is expecting a gene therapy boom. By 2025, the agency expects it will be reviewing and approving about 20 cell and gene therapies annually. There is currently a global shortage of cGMP CDMO capacity for manufacturing viral vectors in support of Gene Therapy.

Our Viral Vector manufacturing technologies

Adeno-associated Virus

Adenovirus

Oncolytic Virus

Retrovirus

Contact Us

We are working to update the content on our website. If you are interested in what we do please contact us and we will get back to you soon.

UEN 202030867M

© 2020-2021 SGVector